Eirion Therapeutics to Present at the 2024 IMCAS WORLD CONGRESS
"IMCAS is one of the premiere aesthetic conferences in the world, and I am excited to showcase Eirion's botulinum product candidates and pipeline progress to my global industry colleagues," commented
IMCAS congresses are medical research conferences focused on providing plastic surgeons and dermatologists with the latest academic and industry updates for their professional progress in the aesthetic field. The primary objective is to build a bridge between aesthetic plastic surgery and dermatology, reinforcing knowledge in each field as well as the areas of study in the junction of the two fields. IMCAS Paris kicks off the IMCAS congress schedule for the year.
About Eirion Therapeutics, Inc.
Eirion Therapeutics, Inc. is a privately held, clinical stage biopharmaceutical company that is developing next-generation prescription products for aesthetic dermatology. Eirion currently has a rich pipeline of products focusing on treatments for wrinkles, primary axillary hyperhidrosis, androgenic alopecia, and hair greying. In the future, Eirion plans to pursue additional indications that address other major unmet clinical needs for physicians and their patients.
To learn more about Eirion, please visit: www.eirionthera.com
Media Contact
EvolveMKD
View original content to download multimedia:https://www.prnewswire.com/news-releases/eirion-therapeutics-to-present-at-the-2024-imcas-world-congress-302050783.html
SOURCE Eirion Therapeutics, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- The Apex Institute Reveals What Hiring Managers Actually Want in Cloud and AI Infrastructure Roles
- MillworkSuite Launches AI Estimating and Direct-to-CAD Platform That Cuts Drafting Time in Half
- ComEd Debuts Mobile Assistance Unit at Waukegan Resource Fair, Bringing On-Site Bill Help Directly to Customers
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share